Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
for Solid Tumors
65 locations incl. Tucson
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT03486873·Phase 3·Recruiting